Effect of Alemtuzumab on Intestinal Intraepithelial Lymphocytes and Intestinal Barrier Function in Cynomolgus Model
Effect of Alemtuzumab on Intestinal Intraepithelial Lymphocytes and Intestinal Barrier Function in Cynomolgus Model作者机构：Department of Biliary Surgery The Affiliated Hospital of Qingdao University Qingdao Shandong 266000 China Department of General Surgery Institute of General Surgery Jinling Hospital Nanjing Jiangsu 210002 China
出 版 物：《Chinese Medical Journal》 (中华医学杂志（英文版）)
年 卷 期：2015年第128卷第5期
页 面：680-686页
核心收录：
学科分类：0710[理学-生物学] 090602[农学-预防兽医学] 07[理学] 09[农学] 0906[农学-兽医学] 071002[理学-动物学]
基 金：This work was supported by grants from the National Basic Research Program (973 Program) in China (No. 2007CB513005 and 2009CB522405) Shangdong Province Young and Middle-Aged Scientists Research Awards Fund (No. BS2011YY004) the Key Project of National Natural Science Foundation in China (No. 30830098) National Key Project of Scientific and Technical Supporting Programs Funded by Ministry of Science and Technology of China (No. 2008BAI60B06) the National Natural Science Foundation in China (No. 3067206t) the Military Scientitle Research Fund (No. 0603AM 117) and the Gut Barrier Foundation of Jie-Shou Li Academician
主 题：Alemtuzumab Barrier Function Infection Intestinal lntraepithelial Lymphocytes Lymphocyte Depletion
摘 要：Background：Alemtuzumab has been used in organ transplantation and a variety of hematologic malignancies （especially for the treatment of B-cell chronic lymphocytic leukemia）.However,serious infectious complications frequently occur after *** reason for increased infections postalemtuzumab treatment is unknown at this *** explore the effect ofalemtuzumab on intestinal intraepithelial lymphocytes （IELs） and intestinal barrier function in cynomolgus model to explain the reason of infection following alemtuzumab ***：Twelve male cynomolguses were randomly assigned to either a treatment or control *** treatment group received alemtuzumab （3 mg/kg,intravenous injection） while the control group received the same volume of physiological *** IELs were isolated from the control group and the treatment group （on day 9,35,and 70 after treatment） for counting and flow cytometric ***,intestinal permeability was monitored by enzymatic spectrophotometric technique and enzyme-linked immunosorbent ***：The numbers of IELs were decreased significantly on day 9 after treatment compared with the control group （0.35 ± 0.07 × 10^8 and 1.35 ± 0.09 × 10^8,respectively; P 〈 0.05） and were not fully restored until day 70 after *** were significant differences among four groups considering IELs *** addition,the proportion ofapoptotic IELs after alemtuzumab treatment was significantly higher than in the control group （22.01 ± 3.67 and 6.01 ± 1.42,respectively; P 〈 0.05）.Moreover,the concentration of D-lactate and endotoxin was also increased significantly on day 9 after ***：Alemtuzumab treatment depletes lymphocytes in the peripheral blood and intestine of cynomolgus *** induction of apoptosis is an important mechanism of lymphocyte depletion after alemtuzumab ***,intestinal barrier function may be disrupted after alemtuzumab treatment.
维普期刊数据库
同方期刊数据库